The Manila Times

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

The ExacTcell™ platform utilizes advanced immunological screening as well as laboratory testing to identify key targets recognized by the immune system across different HLA types. With this expanded ...

TREOS Bio Announces Publication of Phase 1b Clinical Trial Results of PolyPEPI1018 Plus TAS-102 in Refractory MSS mCRC in JCO Oncology Advances

TREOS Bio today announced the publication in Journal of Clinical Oncology - Oncology Advances of results from OBERTO-201 (NCT05130060), a Phase 1b study evaluating PolyPEPI1018, an off-the-shelf multi ...

Research Update

Scancell Holdings plc Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025 Data from SCOPE trial show a potential new benchmark in ...

Scancell reports strong results from Immunobody trial

Scancell Holdings reported strong phase two results for its Immunobody iSCIB1+ cancer immunotherapy on Friday, showing ...

Pluristyx Executes Key Commercial Clinical Use Licenses for iPSC Portfolio, Enabling Novel Therapies for Regenerative Medicine and Neurological Disease Therapeutics

The first agreement grants a license to a pioneering therapeutics company focused on developing a novel iPSC-based treatment for neurological disease. The partnership will leverage Pluristyx's ...
Renal & Urology News

ABO-Incompatible Kidney Transplantation Tested Without Hyperacute Rejection

In a novel ABO-incompatible kidney transplantation, investigators converted the deceased donor kidney’s blood type.

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101Dosed first solid tumor patients with multiplex ...
Le Lézard

Indapta Therapeutics Presents Data Demonstrating Clinical Activity of its Allogeneic Natural Killer Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today ...
Pharmabiz

TScan Therapeutics reaches agreement with US FDA on pivotal study design for TSC-101 and announces strategic prioritization to advance TSC-101

TScan Therapeutics reaches agreement with US FDA on pivotal study design for TSC-101 and announces strategic prioritization to advance TSC-101: Waltham, Massachusetts Wednesday, N ...
Le Lézard

StemCyte Launches First Insurance-Linked Public Cord Blood Access in Taiwan, Setting a New Standard in Cell Therapy Protection

StemCyte International (TPEX: 4178), a global leader in cord blood banking and cell therapy, today announced the launch of its Public Bank Matching Protection Service in Taiwan, developed in ...
Finanznachrichten

TScan Therapeutics, Inc.: TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend ...

Dr. MacBeath continued, "We have a unique opportunity to develop ... trial. The Company plans to expand HLA coverage of the heme program with two additional investigational new drug (IND) applications ...
Newspoint on MSN

Protests by NHM Employees in Assam Demand Equal Pay and Benefits

Following the call from the All Assam Health and Technical Welfare Association (AAHTWA) and the National Health Mission ...